Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
18 October 2018
By
Liz Highleyman
Rapid Initiation of HIV Care: Assessing Safety and Efficacy

Discussion with Gregory Huhn, MD

Published
16 October 2018
From
Infectious Disease Advisor
Doravirine combination works well as a switch option

A combination pill containing doravirine (Delstrigo) maintains undetectable viral load in people with well-controlled HIV who switched therapy, and continues to provide sustained viral suppression at 96

Published
08 October 2018
By
Liz Highleyman
PET Scans May Predict Who Gets Inflammatory Reaction to HIV Treatment Start

The imaging method known as a PET scan may be able to predict who among those starting antiretroviral (ARV) treatment with an immune system highly damaged by HIV will develop HIV-associated immune reconstitution syndrome (IRIS).

Published
26 September 2018
From
Poz
Two new doravirine pills approved in US

The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by

Published
12 September 2018
By
Liz Highleyman
Indonesia: tackling HIV in one of the world’s fastest-growing epidemics

A prospective study that recruited a significant proportion of people newly diagnosed with HIV in four locations in Indonesia and offered them immediate antiretroviral therapy (ART)

Published
04 September 2018
By
Gus Cairns
What you need to know about HIV two-drug regimens

Integrase inhibitors—potent antiretrovirals that quickly and powerfully suppress HIV—have allowed HIV researchers and clinicians to explore dosing regimens that involve fewer than three or four drugs. Proponents of dual therapy say that effective regimens involving fewer drugs will lower costs, decrease pill burden and reduce the potential for drug-drug interactions and side effects. But is it that simple?

Published
28 August 2018
From
BETA blog
Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients

Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients, and people who started treatment very soon after diagnosis were more than

Published
17 August 2018
By
Keith Alcorn
Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment

People receiving dolutegravir-based antiretroviral treatment in Brazil’s national treatment programme were far more likely to have a fully suppressed viral load six months after starting treatment, according

Published
24 July 2018
By
Keith Alcorn
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART

Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in

Published
28 June 2018
By
Michael Carter
← First12345...79Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.